Breaking News Instant updates and real-time market news.

MANH

Manhattan Associates

$61.13

0.96 (1.60%)

, CSL

Carlisle

$128.57

1.94 (1.53%)

18:58
04/23/19
04/23
18:58
04/23/19
18:58

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Manhattan Associates (MANH) up 9.0%... Carlisle (CSL) up 7.1%... Teradyne (TER) up 6.5%... eBay (EBAY) up 4.3%... Snap (SNAP) up 1.3%... Six Flags (SIX) up 1.2%... Navient (NAVI) up 0.6%. ALSO HIGHER: Boston Scientific (BSX) up 0.9% after getting FDA approval for Lotus Edge... AbbVie (ABBV) up 0.8% after getting FDA approval for SKYRIZI. DOWN AFTER EARNINGS: iRobot (IRBT) down 15.2%... Superior Energy (SPN) down 11.5%... Robert Half (RHI) down 10.3%... Total Systems (TSS) down 3.7%... Stryker Corp (SYK) down 3.7%... Edwards Lifesciences (EW) down 2.6%... Texas Instruments (TXN) down 1.9%... TD Ameritrade (AMTD) down 1.9%... Burlington Stores (BURL) down 1.4%... Canadian Pacific (CP) down 1.3%... K12 Inc (LRN) down 1.2%. Movers as of 18:45ET.

MANH

Manhattan Associates

$61.13

0.96 (1.60%)

CSL

Carlisle

$128.57

1.94 (1.53%)

TER

Teradyne

$44.60

-0.26 (-0.58%)

EBAY

eBay

$36.66

0.51 (1.41%)

SNAP

Snap

$11.99

0.46 (3.99%)

SIX

Six Flags

$52.39

0.8 (1.55%)

NAVI

Navient

$12.45

0.38 (3.15%)

BSX

Boston Scientific

$35.88

0.95 (2.72%)

ABBV

AbbVie

$78.65

0.55 (0.70%)

IRBT

iRobot

$130.42

1.71 (1.33%)

SPN

Superior Energy

$4.97

-0.02 (-0.40%)

RHI

Robert Half

$68.83

1.46 (2.17%)

TSS

TSYS

$102.25

1.46 (1.45%)

SYK

Stryker

$186.95

4.905 (2.69%)

EW

Edwards Lifesciences

$180.89

2.64 (1.48%)

TXN

Texas Instruments

$116.37

1.43 (1.24%)

AMTD

TD Ameritrade

$54.28

0.61 (1.14%)

BURL

Burlington Stores

$161.96

1.76 (1.10%)

CP

Canadian Pacific

$219.33

0.215 (0.10%)

LRN

K12

$36.23

0.805 (2.27%)

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 28

    Apr

  • 30

    Apr

  • 01

    May

  • 01

    May

  • 01

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 13

    May

  • 14

    May

  • 14

    May

  • 18

    May

  • 20

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 29

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 05

    Jun

  • 19

    Jun

  • 20

    Jun

  • 26

    Jun

  • 13

    Nov

MANH Manhattan Associates
$61.13

0.96 (1.60%)

10/24/18
RHCO
10/24/18
NO CHANGE
Target $50
RHCO
Hold
Manhattan Associates price target lowered to $50 from $57 at SunTrust
SunTrust analyst Terry Tillman lowered his price target on Manhattan Associates to $50 and kept his Hold rating after its Q3 results, saying that the company's software license revenue was weaker than expected and may remain under pressure into 2019. Tillman notes that while the cloud transition is being "very well managed", the risk-reward on the stock justified a neutral rating.
04/22/19
RHCO
04/22/19
UPGRADE
RHCO
Buy
Manhattan Associates upgraded to Buy from Hold at SunTrust
10/24/18
BNCH
10/24/18
NO CHANGE
Target $60
BNCH
Buy
Manhattan Associates price target lowered to $60 from $69 at Benchmark
Benchmark analyst Mark Schappel said Manhattan Associates' Q3 played out largely as he expected with a mix of positives, such as cloud upside and an improving services business, along with a few negatives, like its license miss and lower cash flow from operations. While he continues to think Manhattan Associates should benefit from an improving retail environment and its product line refresh, he lowered his price target on the stock to $60 to account for the broader software selloff. Schappel keeps a Buy rating on Manhattan Associates shares.
04/22/19
RHCO
04/22/19
UPGRADE
Target $66
RHCO
Buy
Manhattan Associates rises after SunTrust upgrade to Buy on innovation optimism
As previously reported, SunTrust analyst Terry Tillman upgraded Manhattan Associates to Buy from Hold, telling investors in a note published prior to the open that he has become more positive on the company's innovation cycle and long-term dynamics for its cloud solutions. While he anticipates continued stabilizing and "at least in-line" trends through 2019, Tillman noted that his upgrade is not based on a call on Q1 results, which the company is scheduled to report after the close on Tuesday. In terms of specific product innovations that he is excited about, Tillman highlights innovation in the company's on-premise warehouse management system products and the portfolio of Active Omni cloud products. He increased his price target to $66 from $50 on Manhattan Associates shares, which are up 6.5% to $61.01 in early trading.
CSL Carlisle
$128.57

1.94 (1.53%)

02/08/19
OPCO
02/08/19
NO CHANGE
Target $135
OPCO
Outperform
Carlisle price target raised to $135 from $125 at Oppenheimer
Oppenheimer analyst Bryan Blair reiterated an Outperform rating on Carlisle Companies, telling investors in a research note that he believes shares have meaningful room to run over the near-term given its "robust" earnings outlook and discounted valuation. Blair raises his price target to $135, which he says may prove conservative as Carlisle makes further progress towards Vision 2025.
02/19/19
BMOC
02/19/19
NO CHANGE
Target $125
BMOC
Market Perform
Carlisle price target raised to $125 from $115 at BMO Capital
BMO Capital analyst Joel Tiss raised his price target on Carlisle to $125 from $115, saying the results of the company's aggressive restructuring actions, cost containment, and decent volume increases were evident in its 2018 results. The analyst believes that 2019 could turn out to be a "banner year", particularly in light of its balance sheet firepower providing its with "flexibility for ongoing stock buybacks and bolt-on acquisitions." Tiss keeps his Market Perform rating on Carlisle however, stating that in spite of its ample liquidity, he is skeptical of its target to generate 20% operating margin by 2025.
04/05/19
OPCO
04/05/19
NO CHANGE
Target $140
OPCO
Outperform
Carlisle price target raised to $140 from $135 at Oppenheimer
Oppenheimer analyst Bryan Blair reiterated an Outperform rating on Carlisle and raised his price target to $140 from $135. Blair says he refreshed his analysis across Carlisle's segments and remains "highly confident" in significantly improved 2019 profitability. While challenging weather conditions likely impact Q1 construction materials results, the segment's favorable 2019-2020 setup remains intact, Blair contends.
04/09/19
BARD
04/09/19
NO CHANGE
Target $134
BARD
Outperform
Buy Carlisle on weather-related weakness, says Baird
Baird analyst Timothy Wojs says the firm's Roofing Survey indicates that nonresidential roofing volume was up slightly year-over-year in the first quarter despite the negative impact of weather in select regions. Wojs tells investors in a research note that with Carlisle shares having done well year-to-date and that weather creates some modest moving parts in Q1, adding that he is not overly aggressive into the print, but says he would be a buyer of any weather-related Q1 weakness, given his view of reaccelerating EBIT, improved price-cost, and capital deployment over course of 2019. Wojs maintains an Outperform rating and $134 price target on Carlisle shares.
TER Teradyne
$44.60

-0.26 (-0.58%)

01/14/19
EVER
01/14/19
DOWNGRADE
Target $35
EVER
In Line
Teradyne downgraded to In Line from Outperform at Evercore ISI
Evercore ISI analyst C.J. Muse downgraded Teradyne (TER) to In Line from Outperform and lowered his price target to $35 from $45. In a research note to investors, Muse says that while he maintains his positive secular view for Semi demand long-term, he is updating estimates to reflect more modest growth across SOC. The analyst also downgraded Western Digital (WDC) to Underperform from In Line.
02/22/19
CHLM
02/22/19
DOWNGRADE
CHLM
Hold
Teradyne downgraded to Hold from Buy at Craig-Hallum
01/23/19
STFL
01/23/19
NO CHANGE
Target $42.5
STFL
Buy
Teradyne price target lowered to $42.50 from $47 at Stifel
Stifel transferred coverage of Teradyne to Brian Chin, who maintains the firm's Buy rating on the stock but lowered its price target to $42.50 from $47, citing some headwinds in Teradyne's core semi test equipment and industrial automation robotics businesses. He sees the risk of a period of equipment under-utilization and muted seasonality in the semiconductor test business, but still believes the stock remains undervalued, Chin tells investors.
04/05/19
DADA
04/05/19
NO CHANGE
Target $40
DADA
Neutral
Teradyne's appointment of new CFO a 'benefit', says DA Davidson
DA Davidson analyst Thomas Diffely says the appointment of Sanjay Mehta as new CFO by Teradyne following the planned retirement of Gregory Beecher is a positive. The analyst notes that Mehta "inherits an efficient financial model and brings a solid resume of large company experience, including roles at Qualcomm and Nortell". Diffely is also keeping his Neutral rating and $40 price target on Teradyne, stating that its current risk-reward appears "balanced".
EBAY eBay
$36.66

0.51 (1.41%)

03/12/19
BARD
03/12/19
NO CHANGE
Target $40
BARD
Outperform
eBay volume fairly stable in February, says Baird
Baird analyst Colin Sebastian said his survey of completed transactions on eBay.com in February points to slight year-over-year declines, though he thinks this is directionally consistent with management's guidance and his own U.S. gross merchandise volume estimate ex-Stubhub for Q1. Despite the stock approaching his $40 price target, Sebastian said he would be a buyer on pullbacks given the company is now cooperating with activist investors and reviewing its operations and potential strategic alternatives. He maintains an Outperform rating on eBay shares.
04/16/19
BARD
04/16/19
NO CHANGE
BARD
Outperform
Baird lowers eBay Q1 estimate after tracker points to March volume deceleration
Baird analyst Colin Sebastian slightly lowered his Q1 revenue estimate for eBay after his proprietary survey of volume in March suggested a mid-single-digit year-over-year volume decline in gross merchandise volume growth. In total, his Q1 tracker suggests low single-digit declines in GMV, noted Sebastian, who keeps an Outperform rating on eBay shares given the potential he sees for "constructive outcomes" from its strategic review process for the Classifieds and StubHub businesses.
04/08/19
PIPR
04/08/19
NO CHANGE
PIPR
Piper survey of 8,000 teens positive for Ulta, Chipotle, Amazon and Netflix
Piper Jaffray analysts Erinn Murphy, Michael Olson and Nicole Miller Regan say their firm's 37th semi-annual survey of 8,000 teens is more positive for Ulta Beauty (ULTA), VF Corp. (VFC), Lululemon (LULU), Chipotle Mexican Grill (CMG), Amazon.com (AMZN), Netflix (NFLX) and Electronic Arts (EA). The survey results were most cautious for department stores, mid-priced accessories, Ralph Lauren (RL) and eBay (EBAY), the analysts tell investors in a research note. Broadly speaking, the casualization of fashion remains strong, footwear is gaining wallet share, and beauty "remains dynamic" with several indie brands hitting new highs in the survey, say the analysts. They note that Ulta surpassed Sephora as the preferred beauty destination.
04/22/19
KEYB
04/22/19
NO CHANGE
Target $115
KEYB
Overweight
PayPal price target raised to $115 from $110 at KeyBanc
KeyBanc analyst Josh Beck raised his price target for PayPal (PYPL) to $115 from $110, while reiterating an Overweight rating on the shares. The analyst notes that expectations are fairly high following a positive Venmo update last quarter. While he expects TPV headwinds to persist, Beck sees room for credit-driven OVAS to offset. Overall, the analyst remains optimistic on the potential for Venmo monetization, new marketplace agreements, and partnerships to offset the eBay (EBAY) transition.
SNAP Snap
$11.99

0.46 (3.99%)

04/23/19
FBCO
04/23/19
NO CHANGE
Target $13
FBCO
Outperform
Snap price target raised to $13 from $10.50 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Snap to $13 from $10.50 ahead of quarterly results. The analyst notes that the company recently released an updated version of its Android App, which will place it in a better position to address user demand across the globe. Ju now expects 3M incremental users for 2019 versus 1.5M decrease previously. He reiterates an Outperform rating on the shares based on potential for better-than-expected user growth with a revamped Android app, advertising revenue growth acceleration by the second half of the year, and Snap being a scarce asset that offers advertisers access to a coveted younger demographic.
04/18/19
VERF
04/18/19
DOWNGRADE
VERF
Sell
Snap downgraded to Negative from Mixed at Vertical Group
Vertical Group downgraded Snap to Negative citing slowing spending growth, stagnant ROI, and lower inventory.
04/18/19
04/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) downgraded to Neutral from Buy at Citi with analyst Keith Horowitz saying Morgan Stanley reported "strong" Q1 results but the shares are fairly valued. 2. Snap (SNAP) downgraded to Negative from Mixed at Vertical Group and to Neutral from Outperform at Wedbush. 3. Rite Aid (RAD) downgraded with a Sell from Neutral at Guggenheim while Walgreens Boots Alliance (WBA) was downgraded with a Neutral from Buy. 4. CF Industries (CF) downgraded to Underperform from Buy at BofA/Merrill with analyst Steve Byrne saying he has spoken with 10 key channel contacts in the Cornbelt and several commented that never in their 30-plus year careers have they seen fertilizer applications this far behind, mainly due to the weather. 5. FMC Corporation (FMC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the "uncertainty of Rynaxypyr and Cyazypyr patent expiration" as well as the reduced multiple from the recent lithium separation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/22/19
JEFF
04/22/19
NO CHANGE
JEFF
Jefferies still prefers Facebook in social, calls Twitter 'reasonably valued'
Social stocks have outperformed year-to-date, up ~55% versus the Nasdaq's rally of 20%, with Snap (SNAP) being the top performer up 120% after lagging the group in 2018, Jefferies analyst Brent Thill tells investors in a research note. The analyst continues to prefer share of Facebook (FB) in social with a Buy rating and $200 price target. He sees upside in average revenue per user and operating expenditure growth. Meanwhile, Thill is "incrementally positive" on Snap's "encouraging momentum," but says the company is "not out of the woods yet." If Snap can deliver on daily active user growth in Q1 it should be a catalyst for shares, however with the stock trading at nine-times 2019, these improvements are largely priced in, Thill tells investors in a pre-earnings research note. And while the analyst remains "fundamental fans" of Twitter, he views the stock as "reasonably valued." Further, Twitter faces tough comps for international in the first half of 2019 and for the U.S. in the second half of the year, Thill points out.
SIX Six Flags
$52.39

0.8 (1.55%)

03/28/19
RILY
03/28/19
UPGRADE
Target $34
RILY
Buy
SeaWorld upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Eric Wold upgraded SeaWorld Entertainment (SEAS) to Buy from Neutral and raised his price target for the shares to $34 from $30 after taking over coverage from Barton Crockett. The analyst also maintained a Buy rating on Cedar Fair (FUN) and trimmed his firm's price target to $60 from $61. Wold also kept a Buy rating on Six Flags Entertainment (SIX) while lowering its price target to $57 from $72. He has a favorable view of the theme park sector.
03/28/19
RILY
03/28/19
UPGRADE
RILY
Buy
B. Riley upgrades SeaWorld, sees attendance hitting pre-Blackfish levels
B. Riley FBR upgraded SeaWorld Entertainment (SEAS) to Buy from Neutral after transferring coverage of the Theme Park universe to Eric Wold. The analyst raised his price target for the shares to $34 from $30. The stock in premarket trading is down 29c to $48.65. As a leading operator of differentiated theme parks as well as driving animal preservation and education, SeaWorld is well positioned to benefit from increased global consumer brand awareness and improving economies of scale, Wold tells investors in a research note. Further, he sees an attractive opportunity for the company not only to return to attendance levels that were attained prior to the Blackfish fallout six years ago, but to do so with an improved cost structure that will drive strengthening free cash flow and returns to shareholders. The 20% pullback in shares over the past six months provides an attractive opportunity to add to positions, says Wold. He has a positive view of the Theme Park space and kept Buy ratings on Cedar Fair (FUN) and Six Flags Entertainment (SIX).
04/22/19
JEFF
04/22/19
INITIATION
Target $56
JEFF
Hold
Six Flags initiated with a Hold at Jefferies
Jefferies analyst David Katz started Six Flags with a Hold rating and $56 price target. "One of the most impressive business turnarounds of the past decade may have decelerated over the past few quarters," Katz tells investors in a research note. He believes a "measured stance is appropriate" given Six Flags' growth deceleration and leadership transition.
04/22/19
04/22/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Sell at Summit Insights. 2. Agenus (AGEN) initiated with a Buy at B. Riley FBR. 3. Aquestive Therapeutics (AQST) initiated with a Buy at H.C. Wainwright. 4. Akamai (AKAM) initiated with a Buy at Needham. 5. Six Flags (SIX) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NAVI Navient
$12.45

0.38 (3.15%)

06/01/18
06/01/18
UPGRADE
Target $15.75

Outperform
Navient upgraded to Outperform with $15.75 price target at Wedbush
As previously reported, Wedbush analyst Henry Coffey upgraded Navient to Outperform from Neutral, stating that the company's new reporting structure helps him better appreciate the company's earnings outlook and suggests the company is likely to report modest growth in EPS and a total return of over 18% during the next 18 months. Coffey raised his estimates for Navient and increased his price target on the stock to $15.75 from $14.50.
01/16/19
JPMS
01/16/19
UPGRADE
Target $12
JPMS
Neutral
Navient upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Richard Shane upgraded Navient to Neutral while lowering his price target for the shares to $12 from $13.
06/01/18
WEDB
06/01/18
UPGRADE
WEDB
Outperform
Navient upgraded to Outperform from Neutral at Wedbush
01/16/19
JPMS
01/16/19
NO CHANGE
JPMS
JPMorgan resets ratings across Specialty Finance sector
The prospect of a prolonged government shutdown and global trade uncertainty threatens what has been "steady, reliable domestic growth," JPMorgan analyst Richard Shane tells investors in a research note on the Specialty Finance sector. Further, the analyst believes the outlook for Fed action has become more clouded. However, Shane thinks sentiment across his sector seems to reflect uncertainty, which gives him an "increasingly positive bias" to the group. He sees the most upside potential among consumer finance names, with late cycle uncertainty "potentially dampening" upside among commercial mortgage real estate investment trusts. Shane this morning upgraded a host of names: Navient (NAVI), OneMain Holdings (OMF) and KKR Real Estate Finance Trust (KREF) to Neutral from Underweight and TCG BDC (CGBD), Annaly Capital (NLY) and Apollo Commercial (ARI) to Overweight from Neutral. Today's downgrades are Santander Consumer (SC), BlackRock Capital Investment (BKCC), WhiteHorse Finance (WHF) to Underweight from Neutral along with PennantPark (PNNT) and Granite Point Mortgage (GPMT) to Neutral from Overweight.
BSX Boston Scientific
$35.88

0.95 (2.72%)

04/16/19
PIPR
04/16/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific selloff today a buying opportunity, says Piper Jaffray
04/16/19
PIPR
04/16/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific should be bought on surgical mesh selloff, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends using the selloff today in shares of Boston Scientific after the FDA ordered all manufacturers of surgical mesh intended for transvaginal repair to stop selling and distributing their products immediately as a buying opportunity. Mesh products have been declining for several years at Boston Scientific and represented only ~1% of revenue in 2018, O'Brien tells investors in an intraday research note. The analyst estimates the company's revenue will be negatively impacted by less than $50M in 2019. Further, Boston Scientific is currently working with the FDA on a resolution, adds the analyst. Boston Scientific still has a "plethora of high-growth product launches fully intact" including Lotus, Acurate neo, and Watchman in Japan, "which should help cushion any lost revenue," says O'Brien. He has an Overweight rating on the shares with a $42 price target. The stock in afternoon trading is down 4% to $36.34.
04/11/19
PIPR
04/11/19
NO CHANGE
PIPR
Piper sees Nuvectra, Boston Scientific as winners in spinal cord stimulation
After surveying 37 clinicians on the present and future treatment of low back pain, Piper Jaffray analyst Matt O'Brien believes the spinal cord stimulation market is poised to continue "growing quickly." While the survey indicated Nevro (NVRO) and Nuvectra (NVTR) would pick up market share this year, O'Brien believes Boston Scientific (BSX) and Nuvectra will be the "primary share-gainers."
04/16/19
WELS
04/16/19
NO CHANGE
WELS
Boston Scientific mesh sales impacted by FDA recall about $25M, says Wells Fargo
Wells Fargo analyst Larry Biegelsen says that Boston Scientific has informed him that total mesh sales are about $100M and that the products impacted by the FDA recall represent a subset of those sales or about $25M or 0.3% of total sales. The firm had previously stated that the mesh sales impacted by the FDA recall were about $100M in 2018. Biegelsen notes that the lower figure should be "more manageable" for the company. According to the analyst, Boston Scientific is surprised and disappointed by the FDA's decision, which impacts Uphold LITE Vaginal Support System and the Xenform Soft Tissue Repair Matrix for pelvic organ prolapse.
ABBV AbbVie
$78.65

0.55 (0.70%)

03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
03/25/19
ARGS
03/25/19
DOWNGRADE
ARGS
Hold
AbbVie downgraded to Hold from Buy at Argus
03/25/19
03/25/19
DOWNGRADE

Hold
AbbVie downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded AbbVie to Hold, saying its flagship program Humira "no longer looks invulnerable to competition from biosimilars in Europe and other overseas markets." The analyst notes that Humira is also faced with "indirect competition from newer drugs that have an alternative mechanism of action" compared to Humira's anti-TNF class. Toung further cites AbbVie's clinical setback with Venclexta, which highlights the risks for the company as it develops a pipeline aimed to offset the expected decline in Humira sales.
04/11/19
EVER
04/11/19
INITIATION
Target $30
EVER
Outperform
Myovant Sciences initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Myovant Sciences (MYOV) with an Outperform rating and a price targets of $30. The analyst says the company's lead program relugolix has been clinically de-risked with near-term pivotal data readouts. Mehrotra is modeling revenues of $944M for the program by 2023 thanks to its "commercial advantage of a one-a-day pill" and the "second-mover leverage of competitor AbbVie's (ABBV) efforts to raise awareness and diagnosis" in woman's health market.
IRBT iRobot
$130.42

1.71 (1.33%)

03/19/19
03/19/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. ImmunoGen (IMGN) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying the failure of Forward I is a "meaningful setback" for the mirvetuximab development program. 2. Vertex (VRTX) downgraded to Market Perform from Outperform at SVB Leerink with analyst Geoffrey Porges citing the slower ramp of the company's cystic fibrosis products in Europe, the already high expectations priced into the stock and the limited near-term opportunities and catalysts from the company's pipeline. 3. iRobot (IRBT) downgraded to Hold from Buy at Needham with analyst James Ricchiuti stating the market appears to be pricing in expectations of "meaningful upside" to the company's 2019 guidance after the run-up in its stock price this year. 4. Yum! Brands (YUM) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe saying the 9% year-to-date run in shares leaves little upside to estimates. 5. Boeing (BA) downgraded to Hold from Buy at Argus with analyst John Eade stating that he believes company management has not been particularly proactive in its response to two fatal crashes involving the 737 Max jet. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/19/19
03/19/19
DOWNGRADE

Hold
iRobot downgraded to Hold at Needham on valuation
As previously reported, Needham analyst James Ricchiuti downgraded iRobot to Hold from Buy, saying the market appears to be pricing in expectations of "meaningful upside" to the company's 2019 guidance after the run-up in its stock price this year. The analyst notes that while the stock is still not at "peak valuations", it trades "well above" its 5-year average across a variety of valuation metrics. After rising nearly 56% in the last 3 months, Ricchiuti believes that iRobot shares "could take a breather", with the good news likely "priced in at current levels".
04/18/19
JPMS
04/18/19
NO CHANGE
Target $100
JPMS
Neutral
iRobot price target raised to $100 from $88 at JPMorgan
JPMorgan analyst Mark Strouse raised his price target for iRobot to $100 from $88 and keeps a Neutral rating on the shares ahead of the company's "seasonally slow" Q1 results. The analyst expects "continued strong results," though he expects iRobot to keep its revenue guidance unchanged. Management's tone is likely to remain optimistic, particularly regarding the pending launch of the lawnmower product, Terra, and regarding additional product launches later in 2019, Strouse tells investors in a research note. While his price target implies downside, the analyst does not view iRobot as a short as he expects investor optimism regarding new products to "buoy the stock near term."
03/26/19
PIPR
03/26/19
NO CHANGE
Target $96
PIPR
Neutral
iRobot Q1 channel checks inline with expectations, says Piper Jaffray
Channel checks in Q1 indicate demand for iRobot's vacuums were inline with expectations and that retailers' in-stock levels have generally recovered following the "robust" holiday season, Piper Jaffray analyst Troy Jensen tells investors in a research note. The i7 and i7 have "much healthier" in-stock levels following being sold out during the end of 2018, and sales continue to be "strong," adds the analyst. He continues to believe iRobot's competitive fears are easing with no new threat or meaningful share loss to emerging competitors. Jensen, however, reiterates a Neutral rating on iRobot with a $96 price target. He believes the current valuation properly reflects his enthusiasm for iRobot and the robotic vacuum cleaner market.
SPN Superior Energy
$4.97

-0.02 (-0.40%)

03/10/19
GSCO
03/10/19
INITIATION
Target $5.5
GSCO
Neutral
Superior Energy initiated with a Neutral at Goldman Sachs
Goldman Sachs started Superior Energy Services with a Neutral rating and $5.50 price target.
03/15/19
JEFF
03/15/19
NO CHANGE
JEFF
Jefferies downgrades three, upgrades three in Oil Services & Equipment
Jefferies analyst Brad Handler made a handful of rating changes in Oil Services & Equipment. "The harder we look at OFS, the more modest the growth prospects seem," Handler tells investors in a research note. This supports a neutral sector view and favors stock picking, adds the analyst. He downgraded Schlumberger (SLB) to Hold from Buy following the stock's recovery as well as both Helmerich & Payne (HP) and Precision Drilling (PDS) to Hold from Buy on a flat U.S. rig count outlook. Handler also upgraded Oceaneering International (OII) to Buy from Hold citing more confidence in deepwater and a "reasonable" valuation, upgraded Keane Group (FRAC) to Buy from Hold on easing pricing pressure and optionality to put fleets back to work, and upgraded Superior Energy Services to Hold from Underperform. Handler's top picks are Baker Hughes (BHGE), Patterson-UTI (PTEN) and Keane Group. The latter two replace Helmerich & Payne and Apergy (APY).
03/15/19
JEFF
03/15/19
UPGRADE
Target $4
JEFF
Hold
Superior Energy upgraded to Hold from Underperform at Jefferies
Jefferies analyst Brad Handler upgraded Superior Energy Services to Hold from Underperform and raised his price target for the shares to $4 from $3.
02/15/19
SBSH
02/15/19
NO CHANGE
SBSH
Citi views Keane acquisition of FTS as most attractive in Oil Service
Consolidation amongst the pressure pumpers is likely to pick up in the current period of profitability bifurcation, Citi analyst Scott Gruber tells investors in a research note. The analyst, however, believes Schlumberger (SLB) and Halliburton (HAL) seem unlikely to acquire and that consolidation looks more likely amongst the mid-tier pumpers. Of those, Keane Group (FRAC) is most likely to acquire, says the analyst. FTS International (FTSI) screens as the most likely to be acquired, although pumping segments at Patterson-UTI (PTEN) and Superior Energy (SPN) could also be targeted, contends Gruber. He believes Keane and FTS looks like the most attractive combination. Both shares could rise in the event of a deal announcement, says the analyst.
RHI Robert Half
$68.83

1.46 (2.17%)

01/23/19
NRCS
01/23/19
NO CHANGE
Target $45
NRCS
Sell
Robert Half price 'too high', Kelly Services 'attractive', says Northcoast
Northcoast analyst John Healy is keeping his Sell rating and $45 price target on Robert Half (RHI) as part of his broader research note on staffing companies, saying that while business activity in Q4 was in growth mode with a 5.2% reported rate of increase, he sees its stock price as too high. Healy adds that Robert Half's longer term competitive dynamics and margin profile are concerning. The analyst has a positive view on Kelly Services (KELYA) from a risk-reward perspective however, keeping his Buy rating and $31 price target on the shares, as he sees the stock price trading below its intrinsic value.
01/16/19
NOMU
01/16/19
NO CHANGE
Target $80
NOMU
Neutral
Robert Half price target lowered to $80 from $86 at Nomura Instinet
Nomura Instinet analyst Dan Dolev lowered his price target for Robert Half International to $80 ahead of the company's Q4 results and keeps a Buy rating on the shares. The analyst's analysis indicates that Robert Half's temporary placement same-day, constant-currency growth could be 8% in Q4, resulting in 9% overall growth, "only slightly" above the midpoint of the guidance range and roughly in line with consensus estimates.
01/30/19
RHCO
01/30/19
NO CHANGE
Target $70
RHCO
Hold
Robert Half price target lowered to $70 from $76 at SunTrust
SunTrust analyst Tobey Sommer lowered his price target on Robert Half to $70 after its Q4 results, saying that while the company generated higher margins and matched strong consulting demand with higher staff count of its own, he remains concerned by the revenue impact from the slowing macro data in Europe. The analyst kept his Hold rating on Robert Half, even though he is "intrigued by the company's cross-selling consulting and staffing services as a significant potential long-term driver of growth." Sommer also raised his FY19 EPS outlook by 6c to $4.00, adding that the ROIC for Q4 was a standout and "reflects the long term organic growth story" at Robert Half.
04/16/19
RBCM
04/16/19
INITIATION
Target $71
RBCM
Sector Perform
Robert Half initiated with a Sector Perform at RBC Capital
RBC Capital analyst Seth Weber initiated Robert Half with a Sector Perform rating and a price target of $71. The analyst says that it is "hard to argue" with the company's "impressive return on invested capital" and "attractive position", but he also sees the stock becoming less attractive relative to "other staffers" after its strong last-twelve-months and year-to-date performance. Given his anticipated scenario of a slowing macro revenue trajectory, Weber sees Robert Half shares moving "closer to fair value".
TSS TSYS
$102.25

1.46 (1.45%)

03/19/19
KEYB
03/19/19
DOWNGRADE
KEYB
Sector Weight
Worldpay downgraded to Sector Weight after Fiserv deal at KeyBanc
As previously reported, KeyBanc analyst Josh Beck downgraded Worldpay (WP) to Sector Weight from Overweight after the company and FIS (FIS) announced a deal, quickly adding another mega-deal in the wake of Fiserv (FISV)-First Data (FDC) and Global Payments (GPN)-Heartland Payment Systems. The analyst thinks this transaction is likely to expand the M&A discussion around Global Payments, TSYS (TSS), EVO Payments (EVOP), and i3 Verticals (IIIV) and sees paths to accretion should management teams further endorse a scale strategy. Future processing competition could increase among Global Payments, TSYS, First Data, and JPMorgan (JPM), but it remains too early to gauge, he contends.
04/17/19
04/17/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Neutral at JPMorgan and to Outperform from In Line at Evercore ISI. 2. Domino's Pizza (DPZ) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst John Glass saying he thinks the stock's current price reflects 2-3% blended global same store sales growth over the next two years, which he views as too bearish based on its track record as a "best in class operator." 3. TSYS (TSS) upgraded to Buy from Neutral at Goldman Sachs with analyst James Schneider saying the company's new portfolios are driving revenue growth while improving margin expansion is driving earnings acceleration. 4. Omnicom (OMC) upgraded to Equal Weight from Underweight at Barclays. 5. Jones Lang LaSalle (JLL) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Jade Rahmani saying she sees an attractive entry point following the recent underperformance of the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/19
GSCO
04/17/19
UPGRADE
Target $115
GSCO
Buy
TSYS upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst James Schneider upgraded TSYS to Buy from Neutral and raised his price target for the shares to $115 from $98. The company's new portfolios are driving revenue growth while improving margin expansion is driving earnings acceleration, Schneider tells investors in a research note. As a result, the analyst expects TSYS' valuation discount relative to peers to narrow.
03/19/19
SBSH
03/19/19
NO CHANGE
SBSH
Global Payments and TSYS rise on Citi's preferred Payments list
Citi analyst Ashwin Shirvaikar made changes to his stock rankings in the Payments, Processors & IT Services space following FIS' (FIS) acquisition of Worldpay (WP). Global Payments (GPN) and TSYS (TSS) rise towards the top of the analyst's list. Both are "solid" stand-alone ideas but investors should also discuss whether M&A makes sense for either or both names, Shirvaikar tells investors in a research note. The other change made by the analyst was to swap in Square (SQ) to his highest tranche, or "Elite Eight," instead of FleetCor (FLT).
SYK Stryker
$186.95

4.905 (2.69%)

03/15/19
BARD
03/15/19
NO CHANGE
BARD
Stryker, Wright Medical best positioned in medical robotics, says Baird
Following meetings at American Academy of Orthopaedic Surgeons this week, Baird analyst Jeff Johnson said that Stryker (SYK) remained the "clear robotics leader," and added that Smith & Nephew (SNN), Zimmer Biomet (ZBH), and to a lesser extent Johnson & Johnson (JNJ) were all "making progress." The analyst came away most positive on Stryker, due to momentum in multiple pipelines, and Wright Medical (WMGI), due to its core business strength and its intriguing pipeline. Johnson has an Outperform rating and $201 price target on Stryker, and Outperform rating and $36 price target on Wright Medical Group.
03/18/19
BTIG
03/18/19
NO CHANGE
Target $211
BTIG
Buy
Stryker price target raised to $211 from $191 at BTIG
BTIG analyst Ryan Zimmerman raised his price target on Stryker to $211 and kept his Buy rating after its presentation at the recent AAOS conference, saying he is "encouraged" by the company's core business area execution and believes that the adoption of its Mako surgery technology should "continue at a strong pace in FY19". In spite of the increasing competition, the analyst says the management expressed that it has "no plans to change the strategy even in the midst of increasing competition" but rather "noted a slight procedural volume uptick in joint reconstruction".
03/19/19
JPMS
03/19/19
NO CHANGE
Target $215
JPMS
Overweight
Stryker price target raised to $215 from $200 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Stryker to $215 from $200 and reiterates an Overweight rating on the shares. The analyst says that after a "bullish" management dinner, booth tour, and investor meeting, he's even more confident that Stryker can sustain its momentum for the balance of 2019 and a "healthy level" in 2020. The company exited 2018 in a position of strength following a year of peer-high organic growth and operating margin expansion despite meaningful acquisition dis-synergies, Marcus tells investors in a research note partially titled "There's Bullish, and Then There's Stryker's Messaging at AAOS."
04/01/19
WELS
04/01/19
NO CHANGE
Target $219
WELS
Outperform
Stryker price target raised to $219 from $214 at Wells Fargo
Wells Fargo analyst Larry Biegelsen raised his price target for Stryker to $219 from $214 following his monthly MAKO Surgeon Tracker, that analyzes trends in surgeon training. The analyst notes that surgeon training for Stryker's MAKO Total Knee Application was up 1.2% in March month over month as compared to up 2.7% in February. There is typical quarter-to-quarter variation in surgeon training and Biegelsen expects normalized growth going forward versus the high-growth seen in the initial quarters post launch. The analyst continues to believe there is runway for growth as MAKO remains vastly underpenetrated both from a system placement and procedure volume standpoint, globally. He reiterates an Outperform rating on the shares.
EW Edwards Lifesciences
$180.89

2.64 (1.48%)

03/27/19
JPMS
03/27/19
NO CHANGE
Target $190
JPMS
Neutral
Edwards Lifesciences price target raised to $190 from $175 at JPMorgan
JPMorgan analyst Robbie Marcus raised his price target for Edwards Lifesciences to $190 from $175 and keeps a Neutral rating on the shares. The analyst says his doctor survey following the Annual Scientific Session is "very bullish" and supportive of "significant" transcatheter aortic valve replacement market growth in the U.S. Marcus expects TAVR volume growth to accelerate from 15% in 2018 to 19% in 2019 and 22% in 2020. Nonetheless, he remains Neutral on shares of Edwards at current valuation levels. The analyst wants to see evidence of a faster than expected acceleration in the U.S. market, or less share/price loss to competition before looking to revisit his rating.
03/27/19
ADAM
03/27/19
NO CHANGE
Target $215
ADAM
Buy
CMS' TAVR coverage memo positive for Edwards Lifesciences, says Canaccord
Canaccord analyst Jason Mills reiterated a Buy rating on Edwards Lifesciences with a $215 price target, telling investors in a research note that he views the Centers for Medicare and Medicaid Services' proposed Transcatheter Aortic Valve Replacement decision memo as incrementally positive for the TAVR field in general, and an incremental positive for Edwards specifically. The new, proposed TAVR coverage memo, which Mills says is less stringent on specific, prior procedure requirements, updates the requirements for TAVR centers to maintain their status as a TAVR center, and requires the center perform at least 50 AVRs/year, including at least 20 TAVRs/year, or else at least 100 AVRs every two years, at least 40 of which need to be TAVR.
03/25/19
LEHM
03/25/19
NO CHANGE
Target $160
LEHM
Overweight
Edwards Lifesciences price target raised to $160 from $150 at Barclays
Barclays analyst Kristen Stewart raised her price target for Edwards Lifesciences to $160 from $150 after the Partner 3 data that showed the Sapien 3 transcatheter aortic valve was superior to surgery in low risk patients. While the market was broadly expecting superiority, results were very good across the board and better than many expected, Stewart tells investors in a research note. The analyst, however, maintains an Underweight rating on Edwards Lifesciences. She believes the stock is more than pricing the TAVR opportunity and assuming success with mitral. "In this context, we think there could be some risk ahead," Stewart tells investors in a research note.
04/15/19
FBCO
04/15/19
NO CHANGE
Target $221
FBCO
Outperform
Edwards Lifesciences price target raised to $221 from $189 at Credit Suisse
Credit Suisse analyst Matt Miksic raised his price target for Edwards Lifesciences to $221 from $189, while reiterating an Outperform rating on the shares. his bullish outlook is based in part on his view that the company does not yet reflect the low-risk expansion of the TAVR market, and investors appear likely to look past Q1 results toward evidence over the next few quarters of increased TAVR growth following the LR data.
TXN Texas Instruments
$116.37

1.43 (1.24%)

03/25/19
03/25/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Akamai (AKAM) downgraded to Sell from Hold at Deutsche Bank with analyst Vijay Bhagavath saying his estimates for fiscal 2019 through fiscal 2021 are below consensus for both sales and earnings. 2. Nu Skin (NUS) downgraded to Sell from Hold at Stifel with analyst Mark Astrachan saying he sees increasing uncertainty surrounding direct selling companies in China relating to the investigation announced in January into the unlawful promotion and sale of health products. 3. TrueCar (TRUE) downgraded to Hold from Buy at Benchmark with analyst Daniel Kurnos saying he believes it may take several quarters for management to regain credibility, with each quarter heavily scrutinized along the way. 4. Texas Instruments (TXN) and Analog Devices (ADI) downgraded to Market Perform from Outperform at Bernstein. 5. CalAmp (CAMP) downgraded to Neutral from Overweight at JPMorgan with analyst Paul Coster saying he sees limited catalysts for the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/28/19
MSCO
03/28/19
DOWNGRADE
Target $24.5
MSCO
Equal Weight
Quantenna Communications downgraded to Equal Weight at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach downgraded Quantenna Communications (QTNA) to Equal Weight from Overweight and raised his price target on the stock to $24.50 from $18.00 to reflect the company's agreement to be acquired by ON Semiconductor (ON). For ON, Hettenbach estimates a stock buyback would be "meaningfully more accretive over the intermediate term," stating that the company said they expect the deal to be around 5c accretive to EPS but using the same amount of cash to buy back stock at an average price of $22 could add 20c to 2020 EPS. The analyst, who sees other competitors - such as Cypress (CY), Microchip (MCHP) and Texas Instruments (TXN) - being "much better positioned" in low power WiFi, keeps an Underweight rating on ON Semiconductor shares.
04/17/19
LBOW
04/17/19
DOWNGRADE
LBOW
Neutral
Longbow downgrades Texas Instruments, three other semis to Neutral
Longbow analyst Shawn Harrison downgraded Diodes (DIOD), ON Semiconductor (ON), Littelfuse (LFUS) and Texas Instruments (TXN) to Neutral from Buy to reflect a more conservative view of Q2 and second half sales growth relative to consensus expectations. Recent channel checks provided a more cautious view into any recovery given uncertainty in bookings in China and Europe, greater excess inventory than previously realized, and a return of semi pricing pressure, Harrison tells investors in a research note. Valuations also play a role in his downgrades of Littelfuse, Texas Instruments. For Diodes and ON Semiconductor, Harrison believes the slower demand recovery and a return of price declines will "mute clear secular tailwinds and weigh on sentiment, limiting upside."
04/17/19
LBOW
04/17/19
DOWNGRADE
LBOW
Neutral
Texas Instruments downgraded to Neutral from Buy at Longbow
AMTD TD Ameritrade
$54.28

0.61 (1.14%)

03/27/19
WOLF
03/27/19
UPGRADE
WOLF
Peer Perform
TD Ameritrade upgraded to Peer Perform from Underperform at Wolfe Research
01/29/19
MSCO
01/29/19
NO CHANGE
MSCO
Overweight
Morgan Stanley sees 'more to come' from discount brokers after strong Q4
Morgan Stanley analyst Michael Cyprys said the "strong" Q4 earnings reports from Charles Schwab (SCHW), E-Trade (ETFC) and TD Ameritrade (AMTD) showed that the discount brokers can grow revenues in a volatile, late-cycle backdrop. He increased his 2020 top-line estimates across the group, citing expectations for higher net interest margins and higher cash balances. Cyprys, who said the valuations in the group remain compelling on both an absolute and relative basis, keeps Overweight ratings on all three stocks mentioned. He raised his price target on Charles Schwab to $57 from $55, on E-Trade to $62 from $61 and on TD Ameritrade to $64 from $59.
01/04/19
MSCO
01/04/19
NO CHANGE
MSCO
Morgan Stanley says buy TD Ameritrade ahead of earnings, negative on Virtu
Morgan Stanley analyst Michael Cyprys lowered his Q4 EPS estimates by 11% for the Asset Manager and Broker group given that the S&P 500 fell nearly 14% in the quarter, upending what had been a positive year for equity markets up until that point. For 2019, he favors the discount brokers - TD Ameritrade (AMTD), E-Trade (ETFC) and Charles Schwab (SCHW) - given their more defensive earnings profiles. Ahead of the Q4 earnings season he sees TD Ameritrade as "compelling" given its greater skew to trading revenues among the eBrokers, greater derivative mix and rising client cash levels, Cyprys tells investors. He also views concerns around commission price cuts as overdone as doe not expect Charles Schwab to cut, the analyst added. Ahead of Q4 reporting, Cyprys is negative on Virtu Financial (VIRT), as he thinks expectations are too high and notes the stock has recently outperformed.
01/22/19
MSCO
01/22/19
NO CHANGE
Target $57
MSCO
Overweight
Charles Schwab target raised to $57 ahead of winter update at Morgan Stanley
Morgan Stanley analyst Michael Cyprys said he has increased conviction in Charles Schwab (SCHW) shares after the company saw stronger organic deposit growth and broadly strong underlying growth metrics in Q4. He expects Charles Schwab to provide2019 guidance at the company's upcoming Winter Update on February 5 that should meet consensus expectations, but he also expects Schwab to beat those expectations over the course of 2019, as they havve done in prior years. He also expects Charles Schwab to give "more rational" pricing commentary this late in the cycle, which should support the stock and peers TD Ameritrade (AMTD) and E-Trade (ETFC), Cyprys tells investors. He raised his price target on Charles Schwab shares to $57 from $55 ahead of the update call and keeps an Overweight rating on the stock.
BURL Burlington Stores
$161.96

1.76 (1.10%)

03/07/19
DADA
03/07/19
NO CHANGE
Target $193
DADA
Buy
Burlington Stores earnings selloff a buying opportunity, says DA Davidson
DA Davidson analyst John Morris views today's post-earnings selloff in shares of Burlington Stores as a buying opportunity. Missteps in women's and cold-weather categories during Q4, coupled with a choppy start to Q1, has investors questioning management's 2019 guidance for a comp and earnings recovery to near consensus levels, Morris tells investors in a research note. The analyst, however, remains a believer in Burlington management and the secular advantages for the off-price sector. He keeps a Buy rating on the shares with a $193 price target. The stock closed the trading day down 12%, or $19.90, to $147.28.
03/08/19
TLSY
03/08/19
DOWNGRADE
TLSY
Market Perform
Burlington Stores downgraded to Market Perform from Outperform at Telsey
01/16/19
FBCO
01/16/19
NO CHANGE
Target $50
FBCO
Neutral
Nordstrom price target lowered to $50 from $55 at Credit Suisse
Credit Suisse analyst Michael Binetti lowered his price target for Nordstrom (JWN) to $50 from $55 on weak full-price holiday adding to already clearance filled January. With Nordstrom adding to industry markdown issues, the analyst sees negative reads for J.C. Penney (JCP), Kohl's (KSS), Gap (GPS), but positive for Burlington Stores (BURL), Ross Stores (ROST), and TJX (TJX). Binetti reiterates a Neutral rating on Nordstrom shares.
04/16/19
WEDB
04/16/19
NO CHANGE
Target $162
WEDB
Neutral
Burlington Stores price target raised to $162 from $155 at Wedbush
Wedbush analyst Jen Redding raised her price target for Burlington Stores to $162 from $155 saying that her proprietary model for Campaign data positively inflected in Q1, reversing the negative trend forecasted into Q4, and indicating potential for upside to management's guidance reflective of turbulence in the beginning of the quarter. The analyst looks for trends to continue as this year's delayed Easter adds a tailwind to business, increasing the probability of a Q1 beat. While early data insights warned of risk to Q1 gross margins, data recently inflected positively, and now shows the company's run rate tracking above consensus, she adds. Redding reiterates a Neutral rating on the shares.
CP Canadian Pacific
$219.33

0.215 (0.10%)

03/12/19
BERN
03/12/19
DOWNGRADE
BERN
Market Perform
Canadian Pacific downgraded to Market Perform from Outperform at Bernstein
03/12/19
03/12/19
DOWNGRADE

Market Perform
Canadian Pacific downgraded to Market Perform at Bernstein
As previously reported, Bernstein analyst David Vernon downgraded Canadian Pacific to Market Perform from Outperform as he thinks 2019 will represent a peak rate of near-term earnings growth for the company, making it difficult for the stock to re-rate to a higher multiple. While strong execution can help Canadian Pacific deliver bullish top line expectations, Vernon thinks it will be difficult for the company to sustain elevated rates of top line and EBIT growth given the uncertain macro environment. As such, the analyst believes the company will perform more in line with the market over the next year.
04/12/19
DESJ
04/12/19
DOWNGRADE
DESJ
Hold
Canadian Pacific downgraded to Hold from Buy at Desjardins
03/18/19
DBAB
03/18/19
NO CHANGE
DBAB
Deutsche lowers estimates for Canadian Pacific, Canadian National
Deutsche Bank analyst Seldon Clarke lowered his estimates for both Canadian Pacific (CP) and Canadian National (CNI) to reflect weaker than expected volume trends and higher costs related to weather. The analyst, however, remains positive over the mid/long term for both companies given his expectation for "best-in-class" volume growth and continued improvements in profitability. He reduced his price target for Canadian Pacific to $230 from $248.
LRN K12
$36.23

0.805 (2.27%)

01/23/19
BRRR
01/23/19
NO CHANGE
BRRR
K12 price target raised to $30 from $25 at Barrington
Barrington analyst Alexander Paris, Jr. maintained an Outperform rating on K12 and raised his price target on shares to $30 from $25, citing the company's Q2 earnings results beating the firm's expectations, with reported Q2 revenue of $254.9M beating the firm's estimate of $252.0M. The analyst also believes K12 will come in at the higher end of the Q3 guidance range it gave.
01/02/19
SIDC
01/02/19
INITIATION
SIDC
Neutral
K12 initiated with a Neutral at Sidoti
04/12/19
BRRR
04/12/19
NO CHANGE
Target $40
BRRR
Outperform
K12 price target raised to $40 from $30 at Barrington
After hosting meetings with management, Barrington analyst Alexander Paris raised his price target for K12 to $40 from $30 and reiterates an Outperform rating on the shares citing positive macro trends and company execution.
10/24/18
BRRR
10/24/18
NO CHANGE
Target $25
BRRR
Outperform
K12 price target raised to $25 from $22 at Barrington
Barrington analyst Alexander Paris, Jr. raised his price target for K12 Inc to $25 from $22 and maintained an Outperform rating after the company's Q1 results and fall term enrollment topped expectations, the third consecutive fall term enrollment increase and the strongest enrollment growth in six years. In a research note to investors, Paris says he is "encouraged" by the fall term enrollment results, as years of decline, as the company is seeing broad-based demand across virtually all states.

TODAY'S FREE FLY STORIES

YGYI

Youngevity

$6.57

0.13 (2.02%)

, QFIN

360 Finance

$16.46

0.71 (4.51%)

18:55
05/20/19
05/20
18:55
05/20/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

YGYI

Youngevity

$6.57

0.13 (2.02%)

QFIN

360 Finance

$16.46

0.71 (4.51%)

ARWR

Arrowhead

$18.94

-0.52 (-2.67%)

TRIP

TripAdvisor

$44.93

-0.07 (-0.16%)

ASNA

Ascena Retail

$1.13

-0.125 (-9.96%)

KR

Kroger

$24.04

-0.18 (-0.74%)

SNAP

Snap

$11.19

-0.3 (-2.61%)

NDSN

Nordson

$130.42

-4.8 (-3.55%)

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

SWI

SolarWinds

$19.16

0.04 (0.21%)

MRCY

Mercury Systems

$72.85

-0.11 (-0.15%)

VNE

Veoneer

$18.89

0.02 (0.11%)

GH

Guardant Health

$78.29

2.13 (2.80%)

CVNA

Carvana

$67.17

-0.935 (-1.37%)

INSM

Insmed

$28.08

-1.08 (-3.70%)

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 18

    Jun

  • 23

    Jun

  • 10

    Nov

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    Jun

TOL

Toll Brothers

$37.52

-0.88 (-2.29%)

18:47
05/20/19
05/20
18:47
05/20/19
18:47
Hot Stocks
Toll Brothers acquires Sharp Residential, terms not disclosed »

Toll Brothers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

18:45
05/20/19
05/20
18:45
05/20/19
18:45
General news
Breaking General news story  »

Federal Reserve Chairman…

TTWO

Take-Two

$102.94

-3.82 (-3.58%)

18:44
05/20/19
05/20
18:44
05/20/19
18:44
Hot Stocks
Take-Two CEO: Our job is to excite customers »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Nov

AAL

American Airlines

$30.96

-0.8 (-2.52%)

18:40
05/20/19
05/20
18:40
05/20/19
18:40
Periodicals
American Air asks court to halt alleged mechanics unions' slowdown, Reuters says »

American Airlines has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

  • 12

    Jun

  • 12

    Jun

LWAY

Lifeway Foods

$2.75

0.05 (1.85%)

18:38
05/20/19
05/20
18:38
05/20/19
18:38
Earnings
Lifeway Foods reports Q1 EPS (2c) vs. 0c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WHLR

Wheeler REIT

$2.25

0.025 (1.13%)

18:31
05/20/19
05/20
18:31
05/20/19
18:31
Hot Stocks
Wheeler REIT chairman John Sweet to resign »

Wheeler Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$101.54

0.66 (0.65%)

, TGT

Target

$72.10

1.22 (1.72%)

18:03
05/20/19
05/20
18:03
05/20/19
18:03
Periodicals
Judge says Walmart, Target, Bed Bath must face suits over cotton, Reuters says »

U.S. District Judge…

WMT

Walmart

$101.54

0.66 (0.65%)

TGT

Target

$72.10

1.22 (1.72%)

BBBY

Bed Bath & Beyond

$14.48

-0.525 (-3.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

  • 15

    Aug

  • 13

    Nov

QFIN

360 Finance

$16.46

0.71 (4.51%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02
Earnings
360 Finance reports Q1 net income $117.5M, up 382% from last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

MRK

Merck

$78.86

0.15 (0.19%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02
Hot Stocks
Merck falls after Keytruda trial does not meet OS primary endpoint »

Shares of Merck have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

PRIM

Primoris

$20.26

-0.08 (-0.39%)

17:55
05/20/19
05/20
17:55
05/20/19
17:55
Hot Stocks
Primoris director sells 99.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$45.97

-0.11 (-0.24%)

, LM

Legg Mason

$35.68

0.295 (0.83%)

17:44
05/20/19
05/20
17:44
05/20/19
17:44
Hot Stocks
BNY Mellon announces Ed Garden to step down from board of directors »

BNY Mellon (BK) announced…

BK

BNY Mellon

$45.97

-0.11 (-0.24%)

LM

Legg Mason

$35.68

0.295 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DHR

Danaher

$130.33

-0.81 (-0.62%)

17:44
05/20/19
05/20
17:44
05/20/19
17:44
Hot Stocks
VP of Danaher Angela Lalor sells over $408K in company shares »

VP of Danaher Angela…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 07

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$283.95

-2.03 (-0.71%)

17:43
05/20/19
05/20
17:43
05/20/19
17:43
Periodicals
Judge dismisses Trump request to block accounting subpoena, WSJ says »

U.S. District Judge Amit…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$283.95

-2.03 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$35.68

0.295 (0.83%)

17:40
05/20/19
05/20
17:40
05/20/19
17:40
Hot Stocks
Legg Mason names Nelson Peltz, Ed Garden to board of directors »

Legg Mason announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYF

X Financial

$5.42

0.1 (1.88%)

17:34
05/20/19
05/20
17:34
05/20/19
17:34
Earnings
X Financial reports Q1 EPS 24c, consensus 24c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

KTB

Kontoor Brands

$0.00

(0.00%)

, ORN

Orion Group

$2.31

0.02 (0.87%)

17:31
05/20/19
05/20
17:31
05/20/19
17:31
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

KTB

Kontoor Brands

$0.00

(0.00%)

ORN

Orion Group

$2.31

0.02 (0.87%)

VFC

VF Corp.

$90.70

-0.08 (-0.09%)

ARWR

Arrowhead

$18.94

-0.52 (-2.67%)

NAVG

Navigators

$69.99

-0.01 (-0.01%)

HIG

Hartford Financial

$53.13

-0.45 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 06

    Jun

  • 11

    Jun

  • 13

    Nov

BYND

Beyond Meat

$86.10

-3.23 (-3.62%)

17:29
05/20/19
05/20
17:29
05/20/19
17:29
Hot Stocks
Beyond Meat appoints Teri Witteman as General Counsel and Secretary »

Beyond Meat announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ARWR

Arrowhead

$18.94

-0.52 (-2.67%)

, NAVG

Navigators

$69.99

-0.01 (-0.01%)

17:27
05/20/19
05/20
17:27
05/20/19
17:27
Hot Stocks
Arrowhead to replace Navigators in S&P 600 at open on 5/24 »

The Hartford Financial…

ARWR

Arrowhead

$18.94

-0.52 (-2.67%)

NAVG

Navigators

$69.99

-0.01 (-0.01%)

HIG

Hartford Financial

$53.13

-0.45 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

YGYI

Youngevity

$6.57

0.13 (2.02%)

17:25
05/20/19
05/20
17:25
05/20/19
17:25
Earnings
Breaking Earnings news story on Youngevity »

Youngevity backs FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KTB

Kontoor Brands

$0.00

(0.00%)

, ORN

Orion Group

$2.31

0.02 (0.87%)

17:25
05/20/19
05/20
17:25
05/20/19
17:25
Hot Stocks
Kontoor Brands to replace Orion Group in S&P 600 at open on 5/24 »

V.F. Corp. (VFC) is…

KTB

Kontoor Brands

$0.00

(0.00%)

ORN

Orion Group

$2.31

0.02 (0.87%)

VFC

VF Corp.

$90.70

-0.08 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 06

    Jun

  • 13

    Nov

YGYI

Youngevity

$6.57

0.13 (2.02%)

17:25
05/20/19
05/20
17:25
05/20/19
17:25
Earnings
Youngevity reports Q1 EPS (49c), one estimate (1c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$169.34

2.95 (1.77%)

17:22
05/20/19
05/20
17:22
05/20/19
17:22
Hot Stocks
General Dynamics awarded $497.01M Navy contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ISRL

Isramco, Inc.

$110.20

-2.05 (-1.83%)

17:18
05/20/19
05/20
17:18
05/20/19
17:18
Hot Stocks
Isramco enters into $121.40 per share merger pact with Naphtha Israel Petroleum »

Isramco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

PotlatchDeltic

$36.17

-1.31 (-3.50%)

17:16
05/20/19
05/20
17:16
05/20/19
17:16
Hot Stocks
PotlatchDeltic announces changes to Idaho recreation permits »

PotlatchDeltic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.